Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment

被引：11

作者：

Kile, Shawn ^{[1
]}

Au, William ^{[1
]}

Parise, Carol ^{[2
]}

Sohi, Jaideep ^{[3
]}

Yarbrough, Tracy ^{[3
]}

Czeszynski, Alan ^{[4
]}

Johnson, Ken ^{[4
]}

Redline, Dan ^{[4
]}

Donnel, Tammy ^{[2
]}

Hankins, Andrea ^{[2
]}

Rose, Kimberley ^{[1
]}

机构：

[1] Sutter Neurosci Inst, 2800 L St,Suite 500, Sacramento, CA 95816 USA

[2] Sutter Inst Med Res SIMR, Sacramento, CA USA

[3] Northern Calif PET Imaging Ctr, Sacramento, CA USA

[4] NeuroVis, Sacramento, CA USA

来源：

AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS | 2020年 / 35卷

关键词：

intravenous immunoglobulin; mild cognitive impairment; Alzheimer’ s; disease; amyloid; Aβ PET;

D O I：

10.1177/1533317519899800

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Objective: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS). Methods: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed. Results: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye. Conclusions: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.

引用

页数：6

共 34 条

[1] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].

Albert, Marilyn S. ;

DeKosky, Steven T. ;

Dickson, Dennis ;

Dubois, Bruno ;

Feldman, Howard H. ;

Fox, Nick C. ;

Gamst, Anthony ;

Holtzman, David M. ;

Jagust, William J. ;

Petersen, Ronald C. ;

Snyder, Peter J. ;

Carrillo, Maria C. ;

Thies, Bill ;

Phelps, Creighton H. .

ALZHEIMERS & DEMENTIA, 2011, 7 (03) :270-279

[2] Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database [J].

Ben Bouallegue, Faycal ;

Mariano-Goulart, Denis ;

Payoux, Pierre .

ALZHEIMERS RESEARCH & THERAPY, 2017, 9

[3] Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment [J].

Camus, V. ;

Payoux, P. ;

Barre, L. ;

Desgranges, B. ;

Voisin, T. ;

Tauber, C. ;

La Joie, R. ;

Tafani, M. ;

Hommet, C. ;

Chetelat, G. ;

Mondon, K. ;

de la Sayette, V. ;

Cottier, J. P. ;

Beaufils, E. ;

Ribeiro, M. J. ;

Gissot, V. ;

Vierron, E. ;

Vercouillie, J. ;

Vellas, B. ;

Eustache, F. ;

Guilloteau, D. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (04) :621-631

[4]

Chan F.T., 2014, Bionanoimaging: Protein Misfolding Aggregation, P147

[5] Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With Aβ Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue [J].

Choi, Seok Rye ;

Schneider, Julie A. ;

Bennett, David A. ;

Beach, Thomas G. ;

Bedell, Barry J. ;

Zehntner, Simone P. ;

Krautkramer, Michael J. ;

Kung, Hank F. ;

Skovronsky, Daniel M. ;

Hefti, Franz ;

Clark, Christopher M. .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2012, 26 (01) :8-16

[6] Human antibodies against amyloid β peptide:: A potential treatment for Alzheimer's disease [J].

Dodel, R ;

Hampel, H ;

Depboylu, C ;

Lin, SZ ;

Gao, F ;

Shock, S ;

Jäckel, S ;

Wei, W ;

Buerger, K ;

Höft, C ;

Hemmer, B ;

Möller, HJ ;

Farlow, M ;

Oertel, WH ;

Sommer, N ;

Du, YS .

ANNALS OF NEUROLOGY, 2002, 52 (02) :253-256

[7] Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial [J].

Dodel, Richard ;

Rominger, Axel ;

Bartenstein, Peter ;

Barkhof, Frederik ;

Blennow, Kaj ;

Foerster, Stefan ;

Winter, Yaroslav ;

Bach, Jan-Philipp ;

Popp, Julius ;

Alferink, Judith ;

Wiltfang, Jens ;

Buerger, Katharina ;

Otto, Markus ;

Antuono, Piero ;

Jacoby, Michael ;

Richter, Ralph ;

Stevens, James ;

Melamed, Isaac ;

Goldstein, Jerome ;

Haag, Stefan ;

Wietek, Stefan ;

Farlow, Martin ;

Jessen, Frank .

LANCET NEUROLOGY, 2013, 12 (03) :233-243

[8] Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease Rationale and Current Evidence [J].

Dodel, Richard ;

Neff, Frauke ;

Noelker, Carmen ;

Pul, Refik ;

Du, Yansheng ;

Bacher, Michael ;

Oertel, Wolfgang .

DRUGS, 2010, 70 (05) :513-528

[9] Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease [J].

Doody, Rachelle S. ;

Thomas, Ronald G. ;

Farlow, Martin ;

Iwatsubo, Takeshi ;

Vellas, Bruno ;

Joffe, Steven ;

Kieburtz, Karl ;

Raman, Rema ;

Sun, Xiaoying ;

Aisen, Paul S. ;

Siemers, Eric ;

Liu-Seifert, Hong ;

Mohs, Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (04) :311-321

[10] Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity [J].

Du, YS ;

Wei, X ;

Dodel, R ;

Sommer, N ;

Hampel, H ;

Gao, F ;

Ma, ZZ ;

Zhao, LM ;

Oertel, WH ;

Farlow, M .

BRAIN, 2003, 126 :1935-1939

← 1 2 3 4 →